CTI BioPharma Corp. (NASDAQ:CTIC) and Celldex Therapeutics Inc. (NASDAQ:CLDX) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CTI BioPharma Corp.	12.28M	4.82	44.51M	-0.87	0.00
Celldex Therapeutics Inc.	11.23M	5.73	145.62M	-1.16	0.00

Table 1 highlights CTI BioPharma Corp. and Celldex Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows CTI BioPharma Corp. and Celldex Therapeutics Inc.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
CTI BioPharma Corp.	-362.46%	-77.4%	-49.1%
Celldex Therapeutics Inc.	-1,296.71%	-93%	-68.2%

Volatility and Risk

CTI BioPharma Corp.’s volatility measures that it’s 141.00% less volatile than Standard and Poor’s 500 due to its -0.41 beta. Competitively, Celldex Therapeutics Inc.’s beta is 2.61 which is 161.00% more volatile than Standard and Poor’s 500.

Liquidity

The current Quick Ratio of CTI BioPharma Corp. is 3.6 while its Current Ratio is 3.6. Meanwhile, Celldex Therapeutics Inc. has a Current Ratio of 6.6 while its Quick Ratio is 6.6. Celldex Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than CTI BioPharma Corp.

Insider & Institutional Ownership

Roughly 62.1% of CTI BioPharma Corp. shares are held by institutional investors while 29.4% of Celldex Therapeutics Inc. are owned by institutional investors. 0.1% are CTI BioPharma Corp.’s share held by insiders. Comparatively, 0.2% are Celldex Therapeutics Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
CTI BioPharma Corp.	-11.9%	-14.45%	-23.32%	-69.86%	-43.94%	-44.78%
Celldex Therapeutics Inc.	-7.6%	-18.11%	-35.84%	-58.49%	-90.58%	-90.29%

For the past year CTI BioPharma Corp. was less bearish than Celldex Therapeutics Inc.

Summary

CTI BioPharma Corp. beats Celldex Therapeutics Inc. on 8 of the 10 factors.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.